PDCD1 and intrahepatic cholangiocarcinoma: Besides, it has been demonstrated that immune cell density may affect the response to immunotherapy,38 as exemplified by the findings that PD1+ cell was a potential biomarker for anti‐PD‐1‐immunotherapy in head and neck cancer,39 HCC,40 and ICC.41